摘要
目的:探讨慢性阻塞性肺疾病急性加重期(AECOPD)合并肺部感染患者联用莫西沙星与噻托溴铵粉吸入剂的治疗效果。方法:选择80例AECOPD合并肺部感染患者为观察对象,收集时间为2019年1月—2020年12月。分组原则采用遵循随机数字表法,对照组与治疗组各有40例患者。对照组应用噻托溴铵粉吸入剂治疗,治疗组联用莫西沙星与噻托溴铵粉吸入剂治疗。评价两组的治疗总有效率,在治疗前后比较两组1s用力呼气量(FEV1)、最大呼气流速(PEF)、临床肺部感染评分(CPIS),检测血清超敏C反应蛋白(hs-CRP)、降钙素原(PCT)治疗前后的水平变化。结果:治疗组总有效率较对照组的显著提高[92.50%(37/40)VS 72.50%(29/40)],两组之间存在统计学差异(P<0.05)。与治疗前比较,FEV1、PEF两组经过治疗后均升高,CPIS评分经过治疗后均降低(P<0.05);与对照组治疗后比较,治疗组FEV1、PEF治疗后升高,CPIS评分治疗后降低(P<0.05)。与治疗前比较,血清hs-CRP、PCT水平两组经过治疗后均降低(P<0.05);与对照组治疗后比较,治疗组血清hs-CRP、PCT水平治疗后降低(P<0.05)。结论:AECOPD合并肺部感染患者联用莫西沙星与噻托溴铵粉吸入剂的效果满意,患者肺功能及肺部感染情况改善,机体炎症反应得到有效控制。
Objective:To explore the therapeutic effect of moxifloxacin combined with tiotropium bromide powder inhalation in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated with pulmonary infection.Method:80 patients with AECOPD complicated with pulmonary infection were selected as the observation objects,and the collection time was from January 2019 to December 2020.The principle of grouping was to follow the random number table.There were 40 patients in the control group and 40 patients in the treatment group.The control group was treated with tiotropium bromide powder inhaler,and the treatment group was treated with moxifloxacin and tiotropium bromide powder inhaler.Evaluate the total effective rate of the two groups,compare the 1s forced expiratory volume(FEV1),maximum expiratory flow(PEF),clinical pulmonary infection score(CPIS)of the two groups before and after treatment,and detect the changes of serum high-sensitivity C-reactive protein(hs CRP)and procalcitonin(PCT)levels before and after treatment.Result:The total effective rate of the treatment group was significantly higher than that of the control group[92.50%(37/40)VS 72.50%(29/40)],and there was a statistical difference between the two groups(P<0.05).Compared with before treatment,FEV1 and PEF increased after treatment,and CPIs score decreased after treatment(P<0.05);Compared with the control group after treatment,FEV1 and PEF in the treatment group increased after treatment,and CPIs score decreased after treatment(P<0.05).Compared with before treatment,the levels of serum hs CRP and PCT in the two groups decreased after treatment(P<0.05);Compared with the control group after treatment,the levels of serum hs CRP and PCT in the treatment group decreased after treatment(P<0.05).Conclusion:The effect of moxifloxacin combined with tiotropium bromide powder inhalation in patients with AECOPD complicated with pulmonary infection is satisfactory,the pulmonary function and pulmonary infection of patients are improved,and the
作者
蔺志新
Lin Zhixin(Tianjin Ninghe District Hospital of Traditional Chinese Medicine,Tianjin 301500)
出处
《黑龙江医药》
CAS
2022年第5期1087-1090,共4页
Heilongjiang Medicine journal
关键词
慢性阻塞性肺疾病
急性加重期
肺部感染
莫西沙星
噻托溴铵粉吸入剂
Chronic obstructive pulmonary disease
Acute exacerbation
Pulmonary infection
Moxifloxacin
Tiotropium bromide powder inhaler
